Biden's team plans 4 million doses of Covid treatments in January

The treatments include a monoclonal antibody product, pre-exposure preventive drugs for immunocompromised people, and new antiviral pills awaiting Food and Drug Administration authorisation

Joe Biden
Joe Biden (Photo: Reuters)
Bloomberg
1 min read Last Updated : Dec 23 2021 | 12:26 AM IST
The Biden administration expects to take delivery of 4 million courses of Covid-19 treatments by the end of January, according to officials familiar with the matter, sharply ramping up therapies for the disease as the Omicron variant spreads.

The treatments include a monoclonal antibody product, pre-exposure preventive drugs for immunocompromised people, and new antiviral pills awaiting Food and Drug Administration authorisation, the officials said.

The treatments will give doctors a larger arsenal to fight severe coronavirus as the US endures another surge in cases driven by Omicron. The administration has sought to buy a variety of FDA-authorised therapeutics to ensure a mix of effective treatments, part of what the administration is calling its “medicine cabinet,” the officials said. The FDA earlier this month authorised AstraZeneca’s Evusheld, a pre-exposure prevention treatment for the immunocompromised.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Joe BidenCoronavirusUnited States

Next Story